Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Merck-and-CoInc is a drug manufacturers-general business based in the US. Merck-and-CoInc stocks (MRK.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $71.97 – a decrease of 2.41% over the previous week. Merck-and-CoInc employs 73,000 staff and has a trailing 12-month revenue of around $50.4 billion.
Promoted for
Free Trades
Promoted for
Beginners
Promoted for
US Stocks
Promoted for
Advanced Traders
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Since the stock market crash in March caused by coronavirus, Merck-and-CoInc's stock price has had significant negative movement.
Its last market close was $71.68, which is 12.95% down on its pre-crash value of $82.34 and 9.85% up on the lowest point reached during the March crash when the stocks fell as low as $65.25.
If you had bought $1,000 worth of Merck-and-CoInc stocks at the start of February 2020, those stocks would have been worth $760.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $820.74.
| Latest market close | $71.68 |
|---|---|
| 52-week range | $66.6082 - $79.5043 |
| 50-day moving average | $76.0326 |
| 200-day moving average | $74.8557 |
| Wall St. target price | $93.21 |
| PE ratio | 32.4431 |
| Dividend yield | $2.52 (3.5%) |
| Earnings per share (TTM) | $2.196 |
Note: The dollar amounts in the table below are in Canadian dollars.
Historical closes compared with the last close of $71.68
| 1 week (2021-09-09) | -2.90% |
|---|---|
| 1 month (2021-08-19) | -8.64% |
| 3 months (2021-06-18) | -6.44% |
| 6 months (2021-03-19) | -7.52% |
| 1 year (2020-09-18) | -16.40% |
|---|---|
| 2 years (2019-09-18) | -13.59% |
| 3 years (2018-09-18) | 1.87% |
| 5 years (2016-09-16) | 15.18% |
Valuing Merck-and-CoInc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-CoInc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-CoInc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Merck-and-CoInc stocks trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.
Merck-and-CoInc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3485. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-CoInc's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Merck-and-CoInc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$19.9 billion.
The EBITDA is a measure of a Merck-and-CoInc's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | USD$50.4 billion |
|---|---|
| Operating margin TTM | 33.02% |
| Gross profit TTM | USD$34.6 billion |
| Return on assets TTM | 11.47% |
| Return on equity TTM | 20.4% |
| Profit margin | 11.06% |
| Book value | $13.145 |
| Market capitalisation | USD$182.5 billion |
TTM: trailing 12 months
There are currently 27.4 million Merck-and-CoInc stocks held short by investors – that's known as Merck-and-CoInc's "short interest". This figure is 18.3% up from 23.2 million last month.
There are a few different ways that this level of interest in shorting Merck-and-CoInc stocks can be evaluated.
Merck-and-CoInc's "short interest ratio" (SIR) is the quantity of Merck-and-CoInc stocks currently shorted divided by the average quantity of Merck-and-CoInc stocks traded daily (recently around 8.3 million). Merck-and-CoInc's SIR currently stands at 3.32. In other words for every 100,000 Merck-and-CoInc stocks traded daily on the market, roughly 3320 stocks are currently held short.
However Merck-and-CoInc's short interest can also be evaluated against the total number of Merck-and-CoInc stocks, or, against the total number of tradable Merck-and-CoInc stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merck-and-CoInc's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Merck-and-CoInc stocks in existence, roughly 10 stocks are currently held short) or 0.0109% of the tradable stocks (for every 100,000 tradable Merck-and-CoInc stocks, roughly 11 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Merck-and-CoInc.
Find out more about how you can short Merck-and-CoInc stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-CoInc.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-CoInc's overall score of 28.35 (as at 01/01/2019) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck-and-CoInc is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
Merck-and-CoInc's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.55/100
Merck-and-CoInc's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.65/100
Merck-and-CoInc's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-CoInc is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-CoInc scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-CoInc hasn't always managed to keep its nose clean.
Merck & Co. Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.35 |
|---|---|
| Total ESG percentile | 47.16 |
| Environmental score | 3.15 |
| Environmental score percentile | 4 |
| Social score | 15.55 |
| Social score percentile | 4 |
| Governance score | 12.65 |
| Governance score percentile | 4 |
| Level of controversy | 3 |
Dividend payout ratio: 44.01% of net profits
Recently Merck-and-CoInc has paid out, on average, around 44.01% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-CoInc shareholders could enjoy a 3.61% return on their shares, in the form of dividend payments. In Merck-and-CoInc's case, that would currently equate to about $2.52 per share.
While Merck-and-CoInc's payout ratio might seem fairly standard, it's worth remembering that Merck-and-CoInc may be investing much of the rest of its net profits in future growth.
Merck-and-CoInc's most recent dividend payout was on 7 October 2021. The latest dividend was paid out to all shareholders who bought their stocks by 14 September 2021 (the "ex-dividend date").
Merck-and-CoInc stocks were split on a 1048:1000 basis on 3 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-CoInc stocks – just the quantity. However, indirectly, the new 4.6% lower stock price could have impacted the market appetite for Merck-and-CoInc stocks which in turn could have impacted Merck-and-CoInc's stock price.
Over the last 12 months, Merck-and-CoInc's stocks have ranged in value from as little as $66.6082 up to $79.5043. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-CoInc's is 0.4209. This would suggest that Merck-and-CoInc's stocks are less volatile than average (for this exchange).
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Everything we know about the Taseko Mines IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.
Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.
Read more…Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
